Trials / Completed
CompletedNCT05127486
A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic Migraine
A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Galcanezumab Versus Rimegepant in Adult Participants With Episodic Migraine
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 580 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess whether galcanezumab is superior to rimegepant in the prevention of migraine in participants with episodic migraine. The study duration will be approximately 6 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Galcanezumab | Administered SC. |
| DRUG | Rimegepant | Administered orally. |
| DRUG | Placebo | Administered orally. |
| DRUG | Placebo | Administered SC. |
Timeline
- Start date
- 2021-12-06
- Primary completion
- 2023-05-23
- Completion
- 2023-05-23
- First posted
- 2021-11-19
- Last updated
- 2024-06-28
- Results posted
- 2024-06-18
Locations
77 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05127486. Inclusion in this directory is not an endorsement.